Technology | 2017.03.13
BioVentrix announces the 1st Revivent TC™ TransCatheter commercial procedure to treat Ischemic Cardiomyopathy in China
SAN RAMON, Calif., and XIAMEN, China, March 13, 2017 /PRNewswire/ -- BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced commercialization and the first clinical use of its closed-chest Revivent TC™ System in the...
For more information, please visit
http://www.prnewswire.com/news-releases/[...]opathy-in-china-300422225.html
